Johnson & Johnson’s COVID-19 vaccine will remain in limbo for a while longer. That word comes after U.S. health advisers told the government Wednesday that they need more evidence to decide if a handful of unusual blood clots were linked to the shot — and if so, how big the risk really is. The reports are exceedingly rare — six cases out of more than 7 million U.S. inoculations with the one-dose vaccine. But the government recommended a pause in J&J vaccinations this week to provide time to investigate. The CDC expects its advisers to reconsider the evidence within two weeks.
J&J vaccine to remain in limbo while officials seek evidence
